First national analysis of external-beam radiation as bridging therapy finds fewer than 4% of patients prescribed this non-invasive option. People with liver cancer awaiting transplantation could benefit from… read more.
Merck Inc announced that the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib met… read more.
A drug used to treat cirrhosis of the liver may be an effective treatment for a form of Dementia and motorneuron disease, scientists have discovered. The research, led… read more.
Article written by Bruce Sylvester Investigators have validated a first-line combination therapy that significantly improves survival in patients with hepatocellular carcinoma, the most common liver cancer.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
